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 Introduction 
 When AIDS was described in 1981 the disease burden 
was very high. In 1987 the first antiretroviral drugs were 
administered  [1] and benefit for the patient was generally 
very short. Due to the development of resistance and thus 
drug inactivity, the capacity to interfere with HIV repli-
cation was already lost in some patients after 6 weeks. 
Some years later, the phenotypic and genotypic analysis 
of a patient’s HIV by nucleic acid sequencing allowed the 
identification of several key amino acids responsible for 
the induction of resistance. The introduction of new sub-
stances for antiretroviral therapy (ART) caused further 
mutations. In 1997, the analysis of the same amino acid 
mutations in different patients was the beginning of the 
development of interpretation algorithms in centers in 
Paris (Agence Nationale de Recherches sur le Sida; ANRS), 
Leuven (Rega Institute; REGA) and Stanford (Stanford 
University, HIV database; HIVdb).
 Algorithms were initially based on the HIV-1 group M 
subtype B and subsequently extended to further sub-
types. Since 2004/2005 they have included HIV-2 groups 
A and B and quite recently HIV-1 group O. With close 
communication between the centers and open access to 
the interpretation algorithm, the process of learning and 
improving is still continuing.
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 Abstract 
 Antiretroviral drug resistance is mostly linked to a complex 
interaction of several amino acids with variable importance 
or a single amino acid. To facilitate the interpretation of ob-
served mutation patterns, hospital university centers have 
developed several interpretation systems. All the currently 
available interpretation algorithms evolved, are being con-
tinuously updated and have been improved during the last 
decade. Some discrepancies are still evident that are partial-
ly smoothened by link of the individual programs with other 
systems. After the interpretation of HIV-1 group M subtype 
B mutations, a refined algorithm for the other group M sub-
types was developed followed by the interpretation of HIV-1 
group O and HIV-2 mutations. The process of improvement 
is ongoing, due to the better understanding and interpreta-
tion of single and cluster mutations and the availability of 
new antiretroviral substances. The knowledge gained from 
the experience of HIV drug resistance testing has been used 
to establish the interpretation of HBV polymerase mutations 
and will be extended for the treatment of HCV infected with 
protease inhibitors.  Copyright © 2012 S. Karger AG, Basel 
 Published online: January 24, 2012 
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 The enzymes of HIV types and groups are similar but 
also individual. In consequence, some of the amino acid 
mutations that evolve under the drug pressure in HIV-1 
group M subtype B are naturally present in the group O 
virus and in HIV-2. Structural compensation of the virus 
to circumvent the ART drug pressure in group M is dif-
ferent from that in group O and HIV-2, e.g. the cleavage 
sites for the protease (PR) and active site for the reverse 
transcriptase (RT). The effective functioning of the en-
zymes PR and RT evolves under selection pressure and is 
maintained during HIV particle production. In the in-
fected human cell, viral enzyme function is hampered by 
the ART applied only as long as no resistance evolves. To 
delay the generation of drug resistance ART, combination 
therapy is indispensable and the knowledge of which 
drug combination can perform best for the improvement 
of the health status of the patient. For the latter a detailed 
and sophisticated drug resistance interpretation algo-
rithm was developed and remains necessary  [2] .
 ANRS – the Internet address is: http://www.
hivfrenchresistance.org/. First interpretation pro-
grammes were instituted around 2002 and are continu-
ously being improved.
 REGA – the Internet address is: http://jose.med.
kuleuven.be/lab/. For direct determination of the HIV-1 
group M subtype see: http://hivdb.stanford.edu/. HIV-1 
group M subtype interpretation is based on the evalua-
tion of more than 4,000 nucleic acid sequences from 
mostly African patients  [3] . The REGA algorithm can be 
found under: http://jose.med.kuleuven.be/lab/index.
php?id=30. Here, it is indicated that drug resistance inter-
pretation for HIV-2 was available with version 7 in 2007 
and that the latest version was refined in June 2009.
 Stanford HIVdb – the Internet address is: http://hivdb.
stanford.edu/ (see Tang et al.  [4] ).
 Additional data bases for the interpretation of mutated 
amino acids are: geno2pheno (http://www.geno2pheno.
org), see also Thielen and Lengauer  [5] and Lengauer  [6] , 
Virco (http://vircolab.com/) in Pattery et al.  [7] and HIV-
GRADE (http://www.hiv-grade.de/cms/grade/) in Ober-
meier et al.  [8] .
 The algorithms are primarily based on the evaluation 
of subtype B resistance. The resistance interpretation of-
fered also takes into account the naturally occurring ami-
no acid mutations in strains that were not subtype B and 
amino acids that facilitate the generation of resistant 
strains  [2, 9] . Naturally occurring amino acids linked 
with ART drug resistance were especially found in group 
M subtype C and G strains in the PR genome in positions 
20, 36 and 82 ( table 1 )  [10] .
 Interpretation of Amino Acid Mutations in HIV-1 
Group M 
 As already mentioned, all available ART drugs were 
developed in countries where HIV-1 M subtype B shows 
the highest prevalence and these drugs were primarily 
evaluated against subtype B strains. Drug resistance pre-
diction models were trained on results obtained with 
HIV strains grown in culture with a reduced replication 
rate, and taking sequence data of isolates of patients ac-
cording to treatment response and failure. A further way 
of monitoring the efficacy of an algorithm is by a follow-
up of patients whose therapeutic regimen was changed 
because of resistance development and for whom the ben-
eficial drug action in the new combination could be eval-
uated. Identification of the key amino acids leading to 
treatment failure is one item; another is weighing the im-
portance of a single mutation or the combination of sev-
eral mutations in the different parts of the HIV genome. 
In 2003, even within 26 subtype B strains, divergent re-
sults were obtained by 9 available algorithms; the Virco 
and geno2pheno interpretation programs were included 
in this particular study  [11] . Because the system for inter-
pretation is complex, it cannot be avoided that discordant 
results are obtained with different interpretation algo-
rithms.
Table 1. P rotease amino acid resistance mutations
Position M:A M:B M:C M:G O:A O:B O:C HIV-2A HIV-2B
10 I L I I V P P
20 K R I P P
24 L
30 D (N)
36 I M I I I I I I I
46 M I I I
47 G
48 G
50 I
54 I
62 I V V T T T V V
71 A V V V V V
77 V I I I I
84 I L L
90 L
Numbers show the position of selected amino acids that occur 
in the majority of strains of HIV-1 group M subtype A, B, C and 
G, group O clades A, B and C [17], and HIV-2 groups A and B and 
which are responsible for PR inhibitor resistance or impaired ac-
tivity.
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 The study of van de Vijver et al.  [12]  showed a diver-
gence of 25–70% in the results (i.e. resistant and possibly 
resistant) of a virtual phenotypic assay and a genotypic 
interpretation, in strains from 15 European countries, 
e.g. for dideoxyinosine (ddI) using the genotypic ANRS 
and phenotypic virco TYPE algorithm. Despite the re-
ported discrepancies, a considerable convergence of the 3 
interpretation systems ANRS, HIVdb and REGA in 
 1 3,700 patients from Europe was found in the prediction 
of virological response for up to 48 weeks  [13] and 
in  1 4,600 patients from the United States applying the 
ViroSeq intepretation system in addition to these other 3 
 [14] . Results of all studies request further refinement of 
drug-specific genotypic susceptibility scores to improve 
the virological response predictions.
 Drug resistance prevalence is still dependent on the 
frequency of the drug administered, and thus of the en-
forced selection pressure. Single point mutations against 
nucleoside reverse transcriptase inhibitors have been 
found in 74%, against nonnucleoside reverse transcrip-
tase inhibitors in 49% and against PR inhibitors in 36%. 
Dual-drug resistance was present in 46% and triple-drug 
resistance in 20% of all strains  [12] . Among approximate-
ly 500 patients from France and Switzerland, complete 
resistance against 1, 2 or 3 classes of ART drugs was found 
in 37, 15 and 4%, respectively, using the ANRS algorithm 
and in 27, 23 and 24%, respectively, using the HIVdb al-
gorithm  [15] . This discrepancy illustrates how hard it 
may be to reach an unambiguous conclusion, despite the 
efforts made over a decade and the data sets of  1 10,000 
patients.
 Interpretation of Amino Acid Mutations in HIV-1 
Group O 
 This virus has mainly spread in West/Central Africa, 
especially Cameroon, Equatorial Guinea and Gabon 
and is found in patients originating from this region or 
having close contact with people from this region. Some 
100 patients infected with HIV-1 group O are known in 
Portugal and France, as well as a few in Germany, Spain 
and other countries. Group O viruses may be divided 
into 3 major clades, A, B and C, indicating nearly the 
same degree of heterogeneity as the group M virus  [15, 
17] .
 As may be seen in  tables 1–3 , there are some naturally 
occurring amino acid mutations compared to the group 
M virus that are associated with resistance and which 
limit the choice of drugs for specific therapy in group O-
infected patients. The group O virus is resistant to 
NNRTI, while most NRTI and PR inhibitors are active. 
Resistance mutations restricting integrase inhibitors and 
the fusion inhibitor T20 are rarely found  [17] . To amplify 
Table 2. R T and NRTI amino acid resistance mutations 
Amino 
acid 
position
M:A M:B M:C M:G O:A O:B O:C HIV-2A HIV-2B
41 M K
65 (R) K
67 D
69 T
74 L
75 V
77 F
115 Y
151 Q
184 M
210 L Y Y Y G N
215 T
219 K (Q)
S elected amino acid positions for resistance induction of NRTI 
are given compared to HIV-1 group M subtype B, for subtype A, 
C and G, for group O clades A, B and C [17], and for HIV-2A and 
HIV-2B.
Table 3. R T and NNRTI amino acid resistance mutations
Amino 
acid
position
M:A M:B M:C M:G O:A O:B O:C HIV-2A HIV-2B
98 A G/S
100 L
101 K Q Q Q
103 K Q Q Q R R
106 V
108 V
179 V E E E
181 Y C C I I
188 Y L L
190 G A A
N umbers show the position of selected amino acids that oc-
cur in the majority of strains of HIV-1 group M subtype A, B, C 
and G, group O clades A, B and C [17], and HIV-2 groups A and 
B and which are responsible for NNRTI resistance or impaired 
activity.
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the genomic regions of the PR, RT and integrase as well 
as gp41 and the V3 loop, specifically designed primer sets 
differing from those for group M are needed.
 Interpretation of Amino Acid Mutations in HIV-2 
Groups A and B 
 HIV-2 is distributed mainly in West Africa, Angola, 
Mozambique and on the western coast of India. Infected 
people can also be found in European countries. The viral 
load is usually not as high as in HIV-1 infection and the 
decline of CD4 cells is more moderate  [18] . The ANRS 
and REGA resistance algorithms for interpretation have 
been available since about 2004  [19] . 
 As shown in  table  3 , drug susceptibility testing re-
vealed that most of the NRTI were active, while all NNRTI 
were inactive. Within the repertoire of PR inhibitors, am-
prenavir and atazanavir failed to be sufficiently active. 
Inhibition of HIV-2 by enfurtide (T20) was not achieved 
 [20, 21] . Integrase inhibitors are active against HIV-2  [17] . 
Basics for treatment are described by Camacho  [22] .
 Since the number of HIV-2 patients treated with anti-
retroviral drugs is low compared to HIV-1 patients, 
broad experience on the action of ART in patients is not 
available, but the development of resistance may well be 
as fast as in HIV-1 patients  [23, 24] . Viral replication in 
lymphocytes may be high despite the absence of viremia 
 [25] .
 As was mentioned for the group O, virus-specific 
primers have to be used to amplify HIV-2 genes and oc-
casionally it is hard to amplify the 5  region of the RT of 
HIV-2 group B. Participation in international evaluation 
trials is also recommended to maintain a high standard 
of quality control  [26] .
 Compensatory Mutations in Gag 
 Compensatory mutations which lead to restored activ-
ity of the nelfinavir-resistant HIV-1 PR were detected in 
Gag as P453L  [27] . A further structure involved in restor-
ing reduced sensitivity to PR inhibitors seems to be the 
N-terminus of Gag  [28] . Polymorphic mutations at posi-
tions 128, 437 and 449 of HIV-1 Gag seem to be involved 
in a virological response in treatment-naive patients re-
ceiving two PR inhibitors  [29] . Studies of whether similar 
polymorphic mutations are selected in HIV-2 resistance 
are currently not available.
 Compensatory mutations are also found in the enve-
lope proteins: vicriviroc binds to the V3 loop of gp120. 
Resistance to vicriviroc binding is not only dependent on 
amino acid mutations within the V3 loop but may be 
found in compensatory sites in gp41  [30] .
 Drug Resistance and Amino Acid Mutations in the 
Polymerase Gene of HBV 
 The HBV polymerase acts as RT to complete the dou-
ble-stranded circular DNA after liver cell entry. The 
HBV polymerase can be inhibited by some NRTI as la-
mivudine, emtricitabine and tenofovir. Other substanc-
es such as adefovir, entecavir and telbivudine are avail-
able. Drug resistance is partially linked to the YMDD 
motif of the HBV polymerase as observed in the HIV RT 
 [31, 32] .
 HBV drug resistance interpretation systems are avail-
able at HIVdb Stanford, HIV-GRADE and geno2pheno. 
Due to the overlapping reading frames of HBV poly-
merase and HB surface antigen, HIV-GRADE and geno-
2pheno provide not only information on resistance to an-
tiviral drugs but also on immune and detection escape 
variants of HBV.
 Drug Resistance and Amino Acid Mutations in the 
NS3 PR Gene of HCV 
 HCV infection is treated with the combination of pe-
gylated interferon-  and ribavirin. Treatment of HCV 
genotype 1 infection can be essentially improved by ad-
dition of the HCV NS3 PR inhibitors boceprevir (Victre-
lis  , Merck) and telaprevir (Incivu  , Jansen). Drug resis-
tance develops quickly under monotherapy  [33, 34] . As 
has been the experience for HIV and HBV, genotypic as-
says for drug susceptibility evaluation in HCV-infected 
patients who are treated with PR inhibitors are indispens-
able. In the analysis of mutations, a geno2pheno tool is 
also provided for the genotypic determination of drug 
resistance of the so-called direct-acting antiviral agents, 
such as PR (NS3), polymerase (NS5B) and NS5A inhibi-
tors.
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